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Abstract: The present study aimed to evaluate the possible neuroprotective effect of the hydroethanolic extract of Poincianella pyramidalis 
(EHPp) (Tul.) L. P. Queiroz (Fabaceae), an endemic plant found in Northeastern Brazil, commonly used in folk medicine, on the motor 
deficits induced by repeated treatment with reserpine (RES) in rats. Adult male Wistar rats received 10 s.c. injections of 0.1 mg/kg RES or 
vehicle (VR), every 48 h, and daily i.p. injections daily of HEPp (25 mg/kg) or vehicle (VE). Throughout treatment, catalepsy behavior and 
oral movements were scored. After behavioral tests, superoxide dismutase (SOD) and catalase (CAT) activities were evaluated in the 
prefrontal cortex, hippocampus and striatum. RES treatment induced a progressive increase of catalepsy time in the treated group compared 
to control groups starting at day 15. RES also increased the number of vacuous chewing movements, tongue protrusions and duration of 
facial twitching. Treatment with HEPp attenuated the motor deficit in the catalepsy test and delayed the onset of oral movements induced by 
RES. No significant changes were observed in the antioxidant assay. Taken together, these results show a beneficial effect of HEPp on 
motor deficits induced by reserpine, suggesting a neuroprotective effect in a rat model of PD. 
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Resumen: El presente estudio tuvo como objetivo evaluar el posible efecto neuroprotector del extracto hidroalcohólico de Poincianella 
pyramidalis (EHPp) (Tul.) L. P. Queiroz (Fabaceae), en los déficits motores inducidos por el tratamiento repetido con reserpina (RES) en 
ratas. Ratas Wistar machos adultos recibieron 10 inyecciones (s.c.) de 0,1 mg/kg de RES o vehículo (VR) a cada 48 h, y inyecciones (i.p.) 
diarias de EHPp (25 mg/kg) o vehículo (VE). Durante todo el tratamiento se observó el comportamiento de la catalepsia y movimientos 
orales. Después de análisis de comportamientos, fueron evaluados el superóxido dismutasa (SOD) y las actividades de catalasa (CAT) en la 
corteza prefrontal, el hipocampo y el cuerpo estriado. El tratamiento con EHPp atenuó el déficit motor en el ensayo de catalepsia y el retraso 
en el comienzo de los movimientos orales inducidos por RES. No se observaron cambios significativos en el ensayo antioxidante. Estos 
resultados muestran un efecto beneficioso de EHPp en déficits motores inducidos por RES, sugiriendo un efecto neuroprotector en un 
modelo de enfermedad de Parkinson. 
 
Palabras clave: Productos Naturales; Estrés oxidativo; Síntomas motores; Reserpina; Enfermedad de Parkinson. 
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INTRODUCCIÓN 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder after Alzheimer’s disease. 
It is mainly characterized by the loss of dopaminergic 
neurons in the substantia nigra pars compacta and 
further depletion of dopamine terminals in the 
striatum (Lau & Breteler, 2006). The exact 
mechanisms underlying the selective dopaminergic 
cell loss in PD are still poorly understood and the 
majority of cases are idiopathic (Lees et al., 2009). 
However, in both idiopathic and genetic cases of PD, 
oxidative stress has been pointed out as a common 
underlying mechanism that leads to cellular 
dysfunction and death (Janda et al., 2012; Hwang, 
2013). 
The loss of dopaminergic input in the 
striatum is associated with the motor symptoms of 
PD, such as bradykinesia, rigidity and tremor, which 
result in a marked reduction in the quality of life of 
patients (Lees et al., 2009). Treatment involves a 
range of approaches to restore or replace dopamine. 
The most popular pharmacological approach is the 
use of levodopa (L-DOPA), a precursor of dopamine. 
L-DOPA compensates the dopamine deficiency, and 
is still the most effective antiparkinsonian drug 
(Stayte & Vissel, 2014; Olanow, 2015). However, L-
DOPA’s effectiveness is limited in respect to long-
term use, since it undergoes oxidative metabolism, 
which generates reactive oxygen species (ROS). For 
this reason, there is a concern that L-DOPA might be 
toxic to dopaminergic neurons and increase the rate 
of PD’s progression (Olanow, 2015). Thus, the use of 
antioxidants compounds in combination with L-
DOPA could ameliorate side effects of L-DOPA 
therapy. Furthermore, supplementation with 
antioxidants may be useful in the prevention and 
treatment of PD (Prasad et al., 1999). 
Herbal products are valuable sources of 
substances with potential therapeutic value for PD. 
Previous studies indicate that a range of compounds 
derived from herbal extracts, fractions and 
formulations are effective in vitro and in vivo in PD 
models, via modulation of multiple aspects of 
pathogenesis, especially of oxidative stress (Song et 
al., 2012; Fu et al., 2015). Some plant extracts 
possess antioxidant radical-scavenging activities in 
animal models, and their antioxidant effect has been 
associated to polyphenolic compounds (Khurana & 
Gajbhiye, 2013; Rezaei & Alirezaei, 2014). 
Phenolic compounds, represented mainly by 
flavonoids, stand out as the major group of natural 
antioxidants. These substances occur naturally in 
plants and protect them against ROS. 
Neuroprotective effects of flavonoids in pathological 
conditions have been identified (Magalingam et al., 
2015). Therefore, plant extracts that contain these 
substances are interesting candidates for use as 
adjunctive therapy in patients with PD. 
 Poincianella pyramidalis (Tul.) L. P. 
Queiroz (Fabacee) is an endemic tree in the caatinga 
vegetation of Northeastern Brazil, popularly known 
as “catingueira”. Phytochemical and pharmacological 
characteristics of this species remain poorly explored. 
Secondary metabolites have been isolated from P. 
pyramidalis extracts, and flavonoids predominate 
(Bahia et al., 2005). In addition, P. pyramidalis 
extracts exhibit antioxidant activity in vitro and in 
vivo studies (Bahia et al., 2005; Melo et al., 2010; 
Rêgo Jr et al., 2011; Santana et al., 2012; Diniz et al., 
2015). Thus, this plant is a source of natural 
antioxidants, which could be used to reduce or 
preclude the neurodegeneration process in PD. 
Therefore, the aim of present study was to evaluate 
the neuroprotective effect of the hydroethanolic 
extract of P. pyramidalis (HEPp) in rats submitted to 
PD pharmacological model by reserpine. 
 
MATERIALS AND METHODS 
Plant collection and hydroethanolic extraction 
The inner bark of P. pyramidalis was collected in 
Canindé de São Francisco, Sergipe, Brazil, in 
September 2014. A voucher specimen was deposited 
at the Herbarium of the Federal University of Sergipe 
(ASE Number 28.136). Samples were dried at 37° C 
in an oven with air renewal and flow for 48 h until 
complete dehydration. Afterwards, the material was 
crushed with a knife mill and subsequently powdered. 
Then, compounds were extracted by maceration at 
room temperature in 90% ethanol for 7 days. The 
extract was suspended in MeOH/H2O (2:3). The 
percent yield was 5.2% (74.73 g). The HEPp was 
submitted to methods described earlier (Matos, 2009) 
for identification of chemical constituents. 
 
Animals 
Adult male Wistar rats (350 – 450 g) were obtained 
from the Central Animal Facility of the Federal 
University of Sergipe and maintained in the 
Neurophysiology Laboratory. All animals were 
housed in groups of five per plastic cage (30 cm × 37 
cm × 16 cm), under controlled conditions of 
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ventilation, temperature (23 ± 1° C) and a 12/12 h 
light/dark cycle (lights on 6:00 a.m.), with free access 
to water and food. Animals used in this study were 
handled in accordance to the Brazilian law for the use 
of animals in research (Law number 11.794) and 
local ethics committee for animal usage approved all 
the procedures (Protocol number 068/2012). All 
efforts were made to minimize animal pain, suffering 
or discomfort. 
 
Drugs 
Reserpine (RES; Sigma Chemical Co., St. Louis, 
MO, USA) was dissolved in glacial acetic acid and 
then diluted in distilled water at 0.1 mg/mL. Vehicle 
of reserpine (VR) consisted of the same volume of 
glacial acetic acid diluted in distilled water. HEPp 
was suspended in 0.9% saline solution at 25 mg/mL 
and its vehicle (VE) consisted of 0.9% saline. Extract 
and reserpine solutions were prepared daily, shortly 
before administration.  
 
General Procedures and Experimental Design 
Before the beginning of experimental procedures, 
animals were handled daily during 5 min for 5 days. 
Then, rats were randomly assigned to the following 
groups: control (VE + VR; n = 7), RES (VE + RES; n 
= 8), HEPp (HEPp + VR; n = 8) and HEPp + RES 
(HEPp + RES; n = 7). Animals received 10 
subcutaneous (s.c.) injections of RES or VR every 48 
h, and daily intraperitoneal (i.p.) injections of HEPp 
or VE for 20 days. The volume injected was 1 mL/kg 
of body weight in all cases. Previous studies showed 
that repeated administration via s.c. of 0.1 mg/kg of 
RES induces progressive behavioral deficits related 
to clinical symptoms of PD and depletion of tyrosine-
hydroxylase (TH) levels in some brain areas, 
suggesting that the protocol of progressive 
Parkinsonism induction with RES can be useful for 
studying possible neuroprotective interventions for 
PD (Fernandes et al., 2012; Santos et al., 2013; 
Sarmento-Silva et al., 2015).    
Throughout treatment, animals were 
submitted to the following behavioral procedures 
(from 8:00 a.m. to 4:00 p.m.): (1) daily catalepsy test; 
(2) assessment of oral movements on the 14th and 20th 
days (48 h after the 7th and 10th injections of RES and 
VR, respectively). All behavioral tests were 
performed 48 h after the last injection of RES/VR in 
order to avoid acute effects of the drug, and the 
behavioral quantification was performed by direct 
observation with the use of stopwatches by observers 
blinded to treatments. The day of first injection of 
RES was considered day 0. All apparatuses were 
cleaned with 10% ethanol before behavioral testing to 
eliminate odor traces. Experimental design is shown 
in Figure 1. 
 
 
Figure 1 
Schematic representation of the experimental design 
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Behavioral Testing 
Catalepsy Test 
Catalepsy behavior was assessed by placing the 
animal’s forepaws on a horizontal bar positioned 9 
cm above the bench surface. The duration of 
catalepsy, which was defined as an immobile posture, 
keeping both forepaws on the bar, was measured up 
to a maximum of 180 s. Three trials were carried out 
for each animal in each day and the mean value of the 
three trials was used as a data point (Fernandes et al., 
2012;  Santos et al., 2013). 
 
Oral movements 
Rats were individually placed in wire cages (40 cm × 
40.5 cm × 20 cm) with mirrors positioned underneath 
and behind the back wall of the cage to allow for 
behavioral quantification when the animal faced 
away from the observer. The number of tongue 
protrusions (projection of the tongue out of the oral 
cavity), vacuous chewing movement frequency 
(mouth openings in the vertical plane not directed 
toward physical material), and duration of twitching 
of the facial musculature were measured continuously 
for 10 min (Fernandes et al., 2012). 
 
Tissue preparation and oxidative stress parameters 
After the behavioral evaluation on the 20th day (48 h 
after 10 injection of RES/VR), rats were euthanized 
by decapitation. Brains were quickly removed and the 
prefrontal cortex, striatum and hippocampus were 
dissected and weighed. Each area was individually 
homogenized in phosphate-buffered saline (PBS, 50 
mM, pH 7.4) and centrifuged (Heal Force, Neofuge 
15R) for 30 min at 12000-rpm and 4° C. The 
supernatants were used for quantification of catalase 
(CAT) and superoxide dismutase (SOD) activities. 
CAT and SOD activities were assayed as described 
earlier (Madesh & Balasubramanian, 1998; Gioda et 
al., 2010) . Protein content was obtained using the 
method of Lowry (Lowry et al., 1951). 
  
Statistical Analysis 
Data normality and homogeneity of variances were 
assessed by the Shapiro-Wilk and Levene’s tests, 
respectively. Catalepsy behavior and oral movements 
were compared between groups and across treatments 
using two-way ANOVA with repeated measures 
followed by Tukey’s post hoc test. The oxidative 
stress indicators were analyzed by nonparametric 
Kruskal-Wallis test. All significance tests were two-
tailed and p < 0.05 was considered to reflect 
significant differences. All statistical analyses were 
performed using Graph Pad Prism 6.0 (Graph Pad 
Prism Software Inc., San Diego, CA, USA). 
 
RESULTS 
Catalepsy test 
In respect to catalepsy duration across treatments and 
days, a two-way ANOVA with repeated measures 
revealed significant effects of time [F (20,540) = 
23.30, p < 0.001], treatment [F (3, 27) = 13.43, p < 
0.001] and time x treatment interaction [F (60,540) = 
4.77, p < 0.001] (Fig 2). Tukey’s post hoc test 
revealed an increase in catalepsy time of the RES 
group compared to all other groups from the 14th day 
until the 20th day. The HEPp + RES group also 
showed increase in catalepsy time when compared to 
control group on the 16th , 17th, 18th and 20th days and 
to HEPp group only on the 17th and 18th days. 
Furthermore, the HEPp + RES group showed a 
decrease in the catalepsy time when compared to the 
RES group on the 15th, 16th, 17th, 18th, 19th and 20th 
days (Figure 2). 
 
Oral movements 
A two-way ANOVA with repeated measures revealed 
significant effects of time [F (1, 27) = 7.26, p = 0. 
011] and treatment [F(3, 27) = 6.78, p < 0.001], but 
no time x treatment interaction [F(3, 27) = 1.64, p = 
0.203] for the number of vacuous chewing 
movements (VCM) (Fig. 3). The Tukey’s post hoc 
test revealed significant increases in VCM number in 
the RES group on the 14th day when compared to the 
control (p = 0.012) and HEPp (p = 0.012) groups, and 
on the 20th day when compared to control group (p = 
0.028) but not when compared to HEPp (p = 0.077). 
The HEPp + RES group showed no significant 
difference on the 14th day when compared to control 
(p = 0.117), HEPp (p = 0.096) and RES (p = 0.916) 
groups. On the 20th day, the HEPp + RES group 
showed a significant increase of VCM number when 
compared to control (p = 0.002) and HEPp (p = 
0.008) groups, but no difference when compared to 
RES group (p = 0.721) (Figure 3A). 
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Figure 2 
Effects of repeated administration of hydroethanolic extract of Poincianella pyramidalis (HEPp, 25 
mg/kg) or vehicle of extract (VE) on catalepsy behavior of rats treated with 0.1mg/kg reserpine 
(RES) or vehicle of reserpine (VR). The i.p. injections of HEPp or VE were administered daily, 
while the s.c. injections of RES or VR were administered every other day. Data are expressed as 
mean ± S.E.M. (*) p<0.05, (**) p<0.01 for HEPp+RES vs VE+VR; (***) p<0.001 for VR+RES vs 
VE+VR and EHPp+VR; (&)p<0.05, (&&) p<0.01 and (&&&)p<0.001 for VE+RES vs HEPp+RES; 
(#) p<0.05, (##) p<0.01 for HEPp+RES vs HEPp+VR (Two-way ANOVA with repeated measures 
followed by Tukey-s test). 
 
For the number of tongue protrusions, two-
way ANOVA with repeated measures showed 
significant effects of time [F (1, 27) = 6.64, p = 
0.015] and treatment [F (3, 27) = 12.38, p < 0.001], 
but no time x treatment interaction [F (3, 27) = 1.61, 
p = 0.208]. Post hoc analysis revealed an increase in 
the number of tongue protrusions in the RES group 
on the 14th and 20th day when compared to control (p 
= 0.006; p < 0.001, respectively) and HEPp (p = 
0.003; p < 0.001, respectively) groups. The HEPp + 
RES group showed increase only on the 20th day 
when compared to control (p = 0.005) and to HEPp 
(p = 0.018) groups. In addition, no significant 
difference was observed between HEPp + RES and 
RES groups on the 14th and 20th days (Figure 3B). 
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Figure 3 
Effects of repeated administration of hydroethanolic extract of Poincianella pyramidalis (HEPp, 25 mg/kg) 
or vehicle of extract (VE) on number of vacuous chewing movements-VCM (A), number of tongue 
protrusion (B) and duration of facial twitching (C) of rats treated with 0.1mg/kg reserpine (RES) or vehicle 
of reserpine (VR). The i.p. injections of HEPp or VE were administered daily, while the s.c. injections of RES 
or VR were administered every other day. Data are expressed as mean ± S.E.M. (*) p<0.05, (**) p<0.01, 
(***) p<0.001 and (****) p< 0.0001 comparing to VE+VR; (#) p<0.05, (##) p<0.01, (###) p<0.001 comparing 
to HEPp + VR (Two-way ANOVA with repeated measures followed by Tukey-s test). 
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Regarding the duration of facial twitching, 
two-way ANOVA with repeated measures revealed 
time (days of treatment) [F (1, 27) = 4.46, p = 0.044] 
and treatment effects [F (3, 27) = 10.22, p < 0.001], 
but no time x treatment interaction [F (3, 27) = 1.58, 
p = 0.216]. On the 14th day, the RES group showed a 
significant increase in the duration of facial twitching 
when compared to HEPp (p=0.024) but no difference 
when compared to control (p = 0.098) and HEPp + 
RES (p = 0.608). On the 20th day, the RES group 
showed a significant difference when compared to 
control (p < 0.0001) and to HEPp (p < 0.001) groups. 
The HEPp + RES group showed a significant 
increase only on the 20th day when compared to 
control (p = 0.033). In addition, no significant 
difference was observed between HEPp + RES and 
RES groups on the 14th and 20th days (Figure 3C). 
 
Superoxide dismutase (SOD) and catalase (CAT) 
activity 
No significant differences were found for antioxidant 
enzymes in the prefrontal cortex [SOD: H(3) = 2.01, 
p = 0.57; CAT: H(3) = 6.47, p = 0.09], striatum 
[SOD: H(3) = 0.19, p = 0.97; CAT: H(3) = 2.54, p = 
0.46) or hippocampus [SOD: H(3) = 0.54, p = 0.90; 
CAT: H(3) = 1.79, p = 0.61] (Table 1). 
 
Table 1 
Effects of repeated administration of hydroethanolic extract of Poincianella pyramidalis (HEPp, 25 
mg/kg) or vehicle of extract (VE) on superoxide dismutase and catalase activities in prefrontal 
cortex, striatum and hippocampus of rats treated with reserpine (RES) or vehicle of reserpine (VR) 
 
Enzymes 
Brain Region  
Groups Prefrontal Cortex Striatum Hippocampus 
 
Superoxide dismutase  
activity ( U/ mg 
protein) 
VE+VR 0.23 (0.11-0.28) 0.15 (0.03-0.56) 0.06 (0.04-0.12)  
EHPp+VR 0.09 (0.02-1.21) 0.13 (0.03-0.14) 0.07 (0.03-0.09)  
EHPp+RES 0.11 (0.10-0.15) 0.10 (0.02-0.43) 0.05 (0.04-0.20)  
VE+RES 0.10 (0.05-0.18) 0.09 (0.05-0.34) 0.09 (0.05-0.16)  
     
 
Catalase Activity 
 (∆E/min/mg de 
protein) 
VE+VR 0.006 (0.005-0.017) 0.033 (0.006-0.112) 0.007 (0.003-0.024)  
EHPp+VR 0.005 (0.007-0.134) 0.011 (0.009-0.017) 0.004 (0.001-0.012)  
EHPp+RES 0.005 (0.003-0.009) 0.030 (0.013-0.472) 0.005 (0.003-0.224)  
VE+RES 0.017 (0.005-0.090) 0.011 (0.005-0.253) 0.005 (0.003-0.024)  
  
  
 
 
Data are expressed as median (25-75 percentiles). 
DISCUSSION 
In the present study, we investigated the 
neuroprotective and antioxidant effects of the extract 
of P. pyramidalis (HEPp) in rats submitted to 
repeated treatment with a low dose of reserpine. Our 
results show that rats chronically treated with HEPp: 
(1) had decreased duration and delayed onset of the 
catalepsy behavior and (2) had delayed development 
of oral dyskinesia caused by repeated treatment with 
reserpine. 
Reserpine is an inhibitor of vesicular 
monoamine transporter (VMAT), and leads to loss of 
retrieval capacity and hence depletion of monoamines 
in brain and periphery. Reserpine-treated rodent 
model was one of the earliest animal models 
employed in PD research, because it mimics key 
features of symptomatology and neurochemistry of 
PD (Duty & Jenner, 2011; Leão et al., 2015). Acute 
or chronic administration of reserpine induces motor 
impairments, such as hypokinesia, muscle rigidity, 
postural flexion, tremor, oral dyskinesia and 
catalepsy in rodents, resembling PD symptoms in 
humans (Goldstein et al., 1975; Lan & Jiang, 1994; 
Neisewander et al. 1994; Fernandes et al., 2012; 
Santos et al., 2013). 
Catalepsy is expressed as the inability of an 
animal to correct itself from an imposed abnormal 
posture and it has been compared to the inability of 
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patients with PD to initiate movements (Duty & 
Jenner, 2011). Furthermore, this behavior has been 
associated with brain dopamine dysfunction, 
especially in areas involved in PD pathophysiology, 
such as the striatum, globus pallidus and nucleus 
accumbens (Costall & Naylor, 1974; Sanberg et al., 
1988). Accordingly, our results show a gradual 
increase in the duration of catalepsy behavior in rats 
treated with a low dose of reserpine (Figure 2). The 
reserpine-treated group started differing from control 
groups on the 14th day (48 h after 7th reserpine 
injection) corroborating results observed in previous 
studies (Fernandes et al., 2012; Santos et al., 2013; 
Sarmento-Silva et al., 2015).  
Rats submitted to chronic reserpine treatment 
also display oral dyskinesia, characterized by 
twitching of facial musculature, vacuous chewing 
movements and tongue protrusions. Oral movement 
impairments induced by reserpine in rodents are 
suggested to model tardive dyskinesia with features 
similar to parkinsonian tremor  (Neisewander et al., 
1991; Neisewander et al., 1994; Salamone & Baskin, 
1996; Salamone et al., 1998). 
Tardive dyskinesia is characterized by 
abnormal involuntary movements, mainly of the 
tongue and mouth with twisting of the tongue, 
chewing and grimacing movements of the face. It 
may develop after chronic therapy with 
antipsychotics in humans (Casey, 2000; Mathews et 
al., 2005). The majority of PD patients develop 
dyskinesia after chronic treatment with L-DOPA, 
and, unfortunately, no drug is yet approved to treat 
these symptoms. Interestingly, dyskinesia induced by 
reserpine has been used to evaluate compounds with 
possible antiparkinsonian effects in rodent models 
(Salamone et al., 2008; Blanchet et al., 2012; Morin 
et al., 2014). Our results show that reserpine 
treatment induced oral dyskinesia, corroborating data 
in the literature (Neisewander et al., 1994; Fernandes 
et al., 2012; Santos et al., 2013).  
Although the exact mechanisms of 
physiopathology of PD remain unknown, a large 
body of evidence has suggested that oxidative stress 
derived from dopamine metabolism, mitochondrial 
dysfunction and neuroinflammation plays a central 
role in the neuropathology of this disease. 
Accordingly, post-mortem analysis of brain tissue of 
PD patients show increased oxidative stress and 
studies with animal models of PD have supported the 
relationship between oxidative stress and motor 
deficits in rodents (Duty & Jenner, 2011; Janda et al., 
2012; Hwang, 2013).  
Recently, there is increasing interest in 
alternative strategies for treatment or prevention of 
PD by use of medicinal plants. Some antioxidants 
compounds extracted from plants show beneficial 
effects on PD models in vitro and in vivo (Li et al., 
2013), indicating that natural antioxidant compounds 
may be useful to treatment of PD. 
P. pyramidalis is popularly used to treat 
cough, respiratory infections, gastrointestinal 
disorders, injuries and fever (Albuquerque et al., 
2007). Previous studies have shown that P. 
pyramidalis extracts contain phenolic compounds, 
represented mainly by flavonoids (Bahia et al., 2005; 
Silva et al., 2011). Flavonoids are water-soluble 
compounds, synthetized by plants via the 
photosynthesis process and protecting plants against 
reactive oxygen species (ROS). Previous work 
indicates that polyphenols penetrate the blood brain 
barrier (BBB) and exert strong antioxidant activity in 
brain tissue (Frei & Higdon, 2003; Chaturvedi et al., 
2006). Moreover, some studies have shown that 
flavonoids exhibit antioxidant, antiapoptotic and anti-
inflammatory effects and can exert neuroprotective 
effect in pathological conditions, including PD 
(Magalingam et al., 2015).  Interestingly, we showed 
that HEPp decreases the motor alterations and delays 
the onset of the catalepsy behavior induced by 
reserpine, suggesting that HEPp might attenuate the 
brain damage responsible by motor dysfunctions 
through its possible antioxidant action.  
The development of oral dyskinesia induced 
by reserpine is closely related to the oxidative stress 
process (Abílio et al., 2003). Reserpine has been 
employed in the screening for antioxidant treatments 
to motor impairments such as dyskinesia in PD 
models (Abílio et al., 2003; Faria et al., 2005; 
Fernandes et al., 2012; Leão et al., 2015). In this 
work, we show that treatment with HEPp delays the 
development of oral dyskinesia caused by chronic 
treatment reserpine, which might be related to HEP’s 
antioxidant properties. Recent studies have shown a 
significant antioxidant effect of P. pyramidalis 
extracts in vitro and in vivo (Rêgo Jr et al., 2011; 
Santana et al., 2012; Diniz et al., 2015).  
The protective effect of HEPp observed in 
this study may be associated to the constituents in the 
plant extract. Previous phytochemical studies 
revealed that flavonoids are the major components 
found in extracts of P. pyramidalis (Bahia et al., 
2005; Silva et al., 2011; Santos et al., 2011). 
Lins et al. Neuroprotective effect of hydroethanolic extract of Poincianella pyramidalis  
 
Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/158 
 
Therefore, the antioxidant profile of flavonoids may 
be associated with ability of HEPp to prevent the 
neuronal dysfunction induced by reserpine 
administration.  
Unexpectedly, we observed no effects of 
HEPp on the level of antioxidant markers in brain 
tissue. Moreover, we found no alterations in 
oxidative stress parameters due to reserpine 
administration. However, studies evaluating reserpine 
and oxidative stress markers are contradicting. 
Similar to our results, two studies showed that 
reserpine-treated rats with 0.5 mg/kg (Faria et al., 
2005) and 1.0 mg/kg (Abílio et al., 2004) doses 
showed no difference in striatal catalase activity. On 
the other hand, other studies report that chronic 1.0 
mg/kg reserpine treatment decreased SOD and CAT 
activities in rat brain homogenates (Naidu et al., 
2003; Nade et al., 2013), but another study showed 
that same dose increase CAT activity in the striatum 
of rats (Teixeira et al., 2008). These contradictory 
results may emerge from different dosage, treatment 
regimen or brain area analyzed (Leão et al., 2015). 
Further studies are needed to clarify this issue, 
perhaps employing different methods for assaying 
antioxidant activity, like determination of 
thiobarbituric acid reactive substances (TBARS), 
whereas the ethanol extract of P. pyramidalis showed 
a significant reduction of malondialdehyde (MDA) in 
a previous study (Santana et al., 2012). 
Although our results showed no significant 
difference on levels of antioxidant markers in brain 
tissues among the groups, we cannot rule the 
possibility that HEPp may play protective effect 
through different mechanisms, possibly through its 
anti-inflammatory or antiapoptotic activities, due the 
presence of flavonoids (Magalingam et al., 2015). 
However, further studies are required in order to 
identify the components of HEPp and the 
mechanisms underlying the protective effect 
observed in the present study.  
In conclusion, our results demonstrate that 
concomitant treatment with HEPp attenuated 
catalepsy behavior and delayed the development of 
oral dyskinesia induced by chronic treatment with a 
low dosage of reserpine. Importantly, the population 
of Northeastern Brazil makes frequent use of P. p 
yramidalis extracts. The evidence provided here 
suggests that HEPp may be an interesting adjuvant 
treatment of PD since it may delay the onset of the 
neurodegenerative process of PD. Therefore, future 
studies are required to confirm this possible 
therapeutic effect, as well as to clarify its mechanism 
of action. 
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